409O A phase I dose escalation trial of obrixtamig + ezabenlimab in patients (pts) with small cell lung cancer (SCLC) or other neuroendocrine carcinomas (NECs) expressing DLL3

20260 citationsJournal Articlegold Open Access

Authors

Good health and well-being

Published in: ESMO Open

Volume 11, pp. 106723-106723

Field-Weighted Citation Impact: 0.00